To what extent does a trophectoderm (TE) biopsy reliably reflect the chromosomal constitution of the inner cell mass (ICM) in human blastocysts?
Introduction
The implementation of preimplantation genetic testing (PGT) in conjunction with ART rapidly revealed that genetic aberrations are highly prevalent in human embryos (Munné et al., 1993; Harper et al., 2012; Christodoulou et al., 2017) . Furthermore, chromosomal mosaicism, the existence of heterogeneous genetic content within distinct cells or cell populations of a single embryo, became an established phenomenon (Munné et al., 1993; Bielanska et al., 2005; Vanneste et al., 2009) . Chromosomal mosaicism generally results from mitotic errors occurring during the rapid, first cell divisions following fertilisation (Delhanty et al., 1997; Vanneste et al., 2009 ). As such, it is common in cleavage stage embryos (Munné et al., 1994; Mertzanidou et al., 2013) and thought to be less prevalent as development progresses (Los et al., 2004) . The progressive reduction in mosaicism during gestation has been attributed to both complete embryo arrest, as well as the gradual negative selection of abnormal cells (Magli et al., 2000) . However, the recent shift towards next generation sequencing (NGS) and trophectoderm (TE) biopsy within PGT programmes, has led to a number of reports of chromosomal heterogeneity within the blastocyst (Sachdev et al., 2016; Garrisi et al., 2016a Garrisi et al., , 2016b Vera-Rodriguez and Rubio, 2017) . This has raised substantial controversy surrounding the diagnostic accuracy of PGT for aneuploidies (PGT-A), the clinical implications of euploid-aneuploid mosaicism, as well as the added value of high resolution diagnostic techniques. As a single TE biopsy contains approximately four to ten cells, the extent to which it reflects the chromosomal complement of the entire embryo remains unclear.
Recent reports have suggested that mosaic embryos may develop into ongoing pregnancies and healthy live births (Greco et al., 2015; Spinella et al., 2018) , indicating that at present, some potentially viable blastocysts are inadvertently being classified as clinically unsuitable. This is particularly limiting for patients with few or no euploid embryos. To date, transfer policies of many IVF centres have deemed blastocysts with a mosaic diagnosis clinically unsuitable. Greco et al. (2015) hypothesise, however, that the extent and type of mosaicism may affect IVF success rate. While this assumption is plausible, assessing the prevalence of mosaicism remains challenging, particularly at the blastocyst stage of development. To date, opposing estimates of heterogeneity have been reported, ranging from~3 to 40% (Johnson et al., 2010; Capalbo et al., 2013; Sachdev et al., 2017) . However, current results are subject to numerous variables, including different methodologies applied for genetic analysis, while the technical challenges of interpreting sequencing data obtained from a limited number of cells generate further inconsistency.
We sought to assess the distribution of mosaic regions in blastocysts by evaluating chromosomal, NGS profiles of the inner cell mass (ICM) and multiple TE segments obtained from the same embryo. Our lineage comparison of the whole embryo offers a more comprehensive evaluation of the biological variation in blastocysts and provides novel insights into the correlation between mosaicism in the TE and ICM. We evaluated donated embryos with an unknown chromosomal profile obtained from good prognosis patients, as well as PGT-A blastocysts originally diagnosed as abnormal or mosaic. Investigations to date have been predominantly centred on re-analysing embryos following PGT and are thus limited to this patient population (Garrisi et al., 2016a (Garrisi et al., , 2016b Maxwell et al., 2016) . The inaccessibility of human research material has inherently limited the collection of data, which may not be representative of the general IVF demographic. To our knowledge, this is the first study to also assess mosaicism and concordance between the ICM and TE in an unbiased embryo population.
Materials and Methods

Ethical permission and material source
Preimplantation embryos were obtained from patients undergoing ART at the Department for Reproductive Medicine, Ghent University Hospital. Approval for the use of embryos was received from the Institutional Review Board, Ghent University (UZ 2016/1187) and the Belgian Federal Commission for medical and scientific research on embryos in vitro (ADV_070_UZ Gent).
PGT-A was performed within the IVF Center of Ghent University Hospital in collaboration with the Center for Medical Genetics, Ghent University Hospital. All embryos used for this research were donated following cryopreservation with patients' written informed consent.
Experimental design for mosaicism assessment by NGS
We initially carried out a series of cell mixing experiments to establish the sensitivity of NGS to accurately detect chromosomal mosaicism. This was performed by combining aberrant and euploid cells at different ratios, simulating mosaicism for both numerical and structural aberrations (Supplementary Table SI) . We used three B-lymphocyte cell lines with known chromosomal abnormalities obtained from the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository, provided by the Coriell Institute for Medical Research. Lines included GM04927 (47,XY,+21), GM11951 (46,XX,del(18)(q22.1q23)) and GM22998 (46,XX,del(1)(p36.33p36.22)) and were maintained in culture as recommended. Abnormal cells were mixed with a normal, female Blymphocyte cell line (46,XX) in the following ratios: 10:0, 5:5, 4:6, 3:7, 2:8, 0:10. Mixed samples were composed of a total of 10 cells to reflect the sample size of a TE biopsy more accurately.
Individual lymphocytes were manually diluted by serial transfer in phosphate-buffered saline (PBS) (VWR, Leuven, Belgium). Each experiment was performed in triplicate, except for the 10:0 ratio for the three abnormal cell lines and the 5:5 ratio for GM22998 (Supplementary Table SI) . Taken together, a total of 48 samples were collected. Samples were further processed for WGA and subsequent NGS, as described below.
Embryo warming and culture
Cryopreserved cleavage stage embryos, slow-frozen on day 2 or 3 of development, were warmed using the propanediol based EmbryoThaw™ media (Fertipro, Beernem, Belgium), as per manufacturer's instructions.
Embryos were transferred to either Cook Cleavage or Cook Blastocyst Medium (COOK, Limerick, Ireland), depending on the developmental stage at cryopreservation. Embryos warmed on day 2 of development were transferred to Cook Blastocyst Medium on day 3. Embryos were cultured in 25 μL drops under mineral oil (Irvine Scientific, Tilburg, Netherlands) until day 5 or 6 at 37°C, 6% CO 2 and 5% O 2 .
Genetically abnormal blastocysts, vitrified on day 5 or 6 of development and donated following PGT-A, were warmed using the Vitrification Thaw kit (Irvine Scientific, Tilburg, Netherlands), as described (Van Landuyt et al., 2011) . Blastocysts were cultured in Cook Blastocyst Medium for a minimum of 2 h, allowing re-expansion, prior to further processing.
Embryo grading
Blastocysts were scored prior to sampling based on the Gardner and Schoolcraft grading criteria (Gardner and Schoolcraft, 1999) .
Embryo samples
A total of 58 embryos, obtained from 43 patients, were included in the study. Four samples were taken from good quality blastocysts, with a discernible ICM and adequate TE. ICMs were isolated using laser-assisted micromanipulation techniques, as described by Capalbo et al. (2013) . Once the ICM was removed, the TE was further segregated into three portions (Fig. 1 ). All biopsy procedures and dissection steps were performed on an Olympus IX73 microscope fitted with a LYKOS laser (Hamilton Thorne, Beverly, MA, USA), under mineral oil (Irvine Scientific, Tilburg, Netherlands) in Sydney IVF Embryo Biopsy Medium (COOK, Limerick, Ireland). The biopsied portions were washed and collected in PBS.
Sample processing and sequencing
WGA of the cell and embryo samples was performed using the SurePlex DNA Amplification System (Rubicon Genomics Inc., Ann Arbor, MI, Figure 1 Design of study for evaluating chromosomal mosaicism in human blastocysts. We analysed embryos with an unknown chromosomal profile (n = 34) and PGT-A blastocysts, previously diagnosed as abnormal or mosaic (n = 24). Four samples were taken from blastocysts, including the inner cell mass and three distinct trophectoderm portions. Whole genome amplification, followed by next generation sequencing was performed on all embryo samples. Chromosomal profiles were analysed in the Vivar platform. Results were compared between samples from the same embryo, while results from pretested blastocysts were further correlated to the original report. USA), as per manufacturer's instructions. NGS was performed as described by Deleye et al. (2015) with minor modifications. Library construction was performed as per the NEXTflex™ Rapid DNA-Seq Library Prep Kit for Illumina Sequencing (Bioo Scientific, Uden, Netherlands). Genomic DNA was fragmented to an average size distribution of 200 bp using a M220 Focused-ultrasonicator Instrument (Covaris, Woburn, MA, USA). Illumina compatible adapters with barcodes were ligated to the DNA using the NEXTflex™ Ligase Enzyme. Libraries were amplified using the NEXTflex™ PCR Master Mix, after which Agencourt AMPure XP beads (Beckman Coulter, Suarlée, Belgium) were used for purification. Template preparation and Illumina flow cell loading were performed on the cBot™ System (Illumina, San Diego, CA, USA), using 2.5 nM of equimolar pooled libraries. Samples were sequenced on the Hiseq3000 (Illumina, San Diego, CA, USA).
Data analysis
Samples were only included following successful amplification, assessed by fragment analysis (Agilent Bioanalyzer 2100, Agilent Technologies, Palo Alto, CA, USA).
Reads were aligned to the human reference genome NCBI GRCh38, using the Burrow-Wheeler-Aligner Maximal Exact Matches (BWA-MEM) v0.7.5a-r405 algorithm (Li, 2013) and converted to BAM files using SAMtools v0.1.19 (Li et al., 2009) . Subsequent data analysis was performed using the QDNAseq algorithm (Scheinin et al., 2014) , incorporated into the Vivar software (Sante et al., 2014) . This algorithm divides the genome into non-overlapping fixed-sized windows, and counts the number of sequence reads that map within each window. These counts are used to calculate ratios, which are log 2 transformed, resulting in the log 2 relative copy numbers values (log 2 (CN)) used throughout this manuscript. Analysis was performed based on thresholds clinically applied for PGT-A (Deleye et al., 2015) . Chromosomes showing evidence of mosaicism were further evaluated in detail based on our NGS validation data. All data that support the findings of this study are available online in Vivar upon request.
Seventeen samples were excluded from the analysis due to failed amplification or an insufficient number of reads available to achieve the necessary resolution for analysis (Deleye et al., 2015) .
Statistical analysis
In the validation study, the student's t-test for independent samples was used to establish differences between the log 2 (CN) values of the aberrations called in the samples and the euploid baseline. The minimum percentage of aberrant cells showing a significant difference was determined to be the limit of detection for chromosomal mosaicism.
The two-sample t-test for equal variances was used to determine significant differences between maternal age and the incidence of mosaicism, as normality and equal variances were not rejected. Comparison of contingency tables for ICM and TE quality was performed using Fisher's Exact test (two-sided) for the association of embryo quality and mosaicism.
All statistical analyses were performed in R (v3.4.1) (R Foundation for Statistical Computing, Vienna, Austria) or GraphPad Prism (v6.01) (GraphPad Software, San Diego, CA, USA). All P-values <0.05 were considered significant.
Results
Detection of chromosomal mosaicism by NGS
The validation and clinical implementation of NGS for genetic testing of IVF embryos has been previously demonstrated by our group and others (Yin et al., 2013; Wells et al., 2014; Deleye et al., 2015) . To further determine the sensitivity of our platform for detecting chromosomal mosaicism, we combined euploid and abnormal cells at varying ratios. Our findings revealed a linear correlation between the log 2 (CN) values and the number of abnormal cells within each sample (Supplementary Table SI and Fig. S1 ). The limit of detecting chromosomal mosaicism was in some cases as low as 20% (Supplementary Table SI) . However, the size of the aberration considerably affected the detection limit. The 9.5 Mb deletion could only be detected when present in at least 50% of the cells within the test sample (Supplementary Table SI and Fig. S1C ). As such, we restricted our analysis to aberrations >10 Mb in size. This is in line with recommendations for reporting sub-chromosomal copy number variations in PGT-A (Capalbo et al., 2017a) . Taken together, we demonstrate the ability of NGS to reliably detect both numerical and structural aberrations when present in as low as 3 out of 10 cells, at a resolution >10 Mb. (Supplementary  Table SI 
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Blastocysts contain a high rate of chromosomal mosaicism, with no preferential lineage allocation of abnormal cells
We primarily evaluated embryos with an unknown chromosomal profile. These were obtained from good prognosis patients, donated following standard IVF/ICSI cycles (n = 34 embryos). Four samples were taken from good quality blastocysts, including the whole ICM and three TE portions (Fig. 1 ). Within this embryo group, the overall concordance between the ICM and all TE samples was 55.9%. Of these, 41.2% were euploid, while 14.7% were abnormal, with consistent results across all biopsies (Table I) . We determined chromosomal mosaicism in up to 44.1% of the blastocysts analysed (Table I ). The mosaic abnormalities observed involved numerical aneuploidies, as well as several distinct structural aberrations (Table II) . Remarkably, a normal ICM was detected in 20.6% of the total blastocysts, for which at least one TE sample showed a full or mosaic chromosomal aberration (Table I) . Conversely, 17.6% of the total embryos presented with mosaic or full aneuploidies within the ICM, while showing normal or mosaic TE profiles (Tables I and II) . We observed no preferential allocation of aberrant cells to either embryonic lineage. Moreover, we determined chaotic mosaicism in 20.6% of the total blastocysts analysed (Table II) . These embryos contained several populations of cells with mosaic abnormalities involving multiple chromosomes (Delhanty et al., 1997) . We identified further evidence of mosaicism in two meiotically aneuploid blastocysts (Table I) . Although these embryos contained several aberrations uniformly detected across all segments (ICM and TE), they presented with additional, unique chromosomal variants confined to the TE (Table II) .
The distribution of mosaicism within the blastocyst confirms the occurrence of mitotic errors, including mitotic non-disjunctions
In three (out of seven) embryos with a euploid ICM, we detected mosaicism involving the same chromosome in different portions of the TE (Table II) . For two embryos, the abnormality appeared to be mosaic in one TE segment and present in a higher proportion of cells within another ( Fig. 2A and Supplementary Fig. S2 ). Moreover, one embryo (out of seven) presented with a reverse aneuploidy detected in two independent TE samples, revealing strong evidence of a mitotic non-disjunction (Fig. 2B) .
When considering embryos with a mosaic or abnormal ICM and mosaic TE, three (out of five) presented with at least one euploid TE profile. Remarkably, all of these embryos (five out of five) showed further evidence of the same, full or mosaic ICM aberrations within the TE (Table II) . Furthermore, we observed reciprocal chromosomal errors in independent intra-embryo samples in four (out of these five) embryos ( Fig. 3A and B, Supplementary Fig. S3A, B) . One embryo, presented with several mosaic monosomies within its ICM. We could not confirm the presence of any of these ICM aberrations within the TE, with all three TE biopsies presenting with normal profiles (Supplementary Fig. S4 ).
The complex nature of blastocyst mosaicism inherently confounds the diagnostic accuracy of a single TE biopsy
To estimate the diagnostic accuracy of a TE biopsy in predicting the chromosomal constitution of the ICM, we evaluated sensitivity and specificity in the context of PGT-A. Concordance of the TE and ICM was calculated using classifications as true positive (abnormal ICM, abnormal TE), true negative (normal ICM, normal TE), false negative (abnormal ICM, normal TE) or false positive (normal ICM, abnormal TE), within the untested embryo group. The TE was considered abnormal if the aberration was detected in at least one sample. Based on this evaluation, sensitivity (the probability of an abnormality in the ICM being diagnosed from a TE biopsy) was 90.9% (10 out of 11). Moreover, specificity (the proportion of embryos with a normal ICM diagnosed as clinically suitable), as per TE biopsy, was 66.7% (14 out of 21). Based on our findings we estimate an overall diagnostic accuracy of 75%.
To further assess the association between mosaicism in a TE biopsy and the chromosomal status of the embryo, we re-analysed blastocysts previously classified as clinically unsuitable, following PGT-A (n = 24). Once again, we isolated the ICM and segregated the TE into three portions (Fig. 1) . Blastocysts within our pretested group were originally diagnosed as either abnormal (n = 8), mosaic (n = 8) or as having both a uniform and mosaic chromosomal aberration involving distinct chromosomes (n = 8) ( Table III) .
The overall concordance between the ICM and all re-biopsied TE samples for the pretested embryos was 70.8% (17 out of 24) (Tables III and  IV) . When compared to the original biopsy, we determined a high concordance for uniform abnormalities, however mosaic aberrations were confirmed with a lower frequency (Table IV) . Interestingly, embryos originally reported as uniformly abnormal (n = 8) did not reveal any evidence of chromosomal mosaicism (Table III) 50.0% (8 out of 16 embryos) matched the original mosaic diagnosis (n = 8), presenting with either a full or reverse aberration, or confirming the abnormality in mosaic form in at least one blastocyst portion (Table IV) . However, we confirmed the mosaic abnormality in the ICM and all three TE portions in only one embryo, while for two embryos, the mosaic abnormality was present in the ICM and some, but not all TE segments. Moreover, the original mosaic aberration was confirmed exclusively in the TE in four embryos (Table IV) , while for embryo X4.2, the abnormality was limited to the ICM (Table IV) . Remarkably, five blastocysts originally diagnosed as mosaic, displayed a euploid ICM profile and normal results in all three TE biopsies (Fig. 4A, Table IV ). Of these, however, a re-biopsied TE sample from one embryo did suggest a structural gain, reciprocal to the deletion detected in the original TE biopsy. Although not called by our algorithm, these two aberrations presented with identical breakpoints (Fig. 4B) . We could not confirm mosaicism in three embryos originally diagnosed with both mosaic and full aneuploidies. Here, we could only verify uniform abnormalities in the embryo portions (Table IV) .
Patient parameters are not associated with the prevalence of mosaicism
The embryos investigated in our untested group were obtained from good prognosis patients (n = 25), with maternal age ranging from 23 to 39 years, with a mean of 32.2 years (Table II) . Patients were considered good prognosis based on age and live birth outcomes. More specifically, 96.0% of the patients achieved a live birth within four cycles, while 70.0% of patients had a live birth within their first cycle.
We could not observe a significant effect of age on embryo mosaicism (P = 0.101). Similarly, ICM and TE quality were not found to affect the occurrence of mosaicism (P = 0.718 and P = 0.462, respectively). This was also the case for the pretested embryos, for both age (P = 0.7309), as well as ICM and TE quality (P = 1.000 and P = 0.2885). Here, maternal age ranged from 23 to 40 years (mean 32.6 years, n = 18) (Table IV) . Interestingly, analysis of six embryos obtained from the same patient (P9) within the untested embryo group revealed an even distribution of aneuploid, euploid and mosaic embryos (Table II) .
Discussion
The present analysis provides a comprehensive comparison of the ICM and multiple TE portions obtained from the same embryo. We determine chromosomal mosaicism in up to 37.9% of the total embryos analysed, indicating that blastocysts harbour a higher rate of chromosomal heterogeneity than previously estimated. Moreover, we show variability amongst embryos and a relatively low correlation between mosaicism in the TE and the ICM.
Recent reports of chromosomal mosaicism with the use of NGS have generated intense debate regarding the diagnostic accuracy of PGT-A, specifically the predictive value of a TE biopsy to reflect the chromosomal status of the entire embryo. Our findings reveal an overall high sensitivity in the context of PGT-A, as aberrations detected in the TE were confirmed in the ICM in over 90% of cases. However, specificity was determined to be 67%, suggesting that a considerable proportion of embryos are potentially classified as unsuitable for transfer, ensuing a false positive diagnosis based on the TE biopsy result. Within our untested group, all embryos considered as false positives presented with chromosomal mosaicism within the TE. Moreover, within the pretested group, only one embryo with a normal ICM contained a TE segment presenting with a uniform aberration. As such, low specificity appears to be primarily associated with the diagnosis of mosaicism. Given the high rate of mosaicism in human embryos, mosaic blastocysts are inevitably being transferred during routine IVF cycles. Therefore, if a certain proportion of mosaic blastocysts can achieve viable pregnancies, treatment outcomes are undoubtedly compromised by their exclusion. Nevertheless, the implantation and developmental potential of embryos with a euploid ICM and mosaic or abnormal TE currently remains unknown.
Notably, our results reveal varying levels of mosaicism amongst samples from the same embryo. Therefore, the chromosomal heterogeneity observed in a single TE biopsy may not always be indicative of the rate of mosaicism for the entire blastocyst. The validation of our NGS platform suggests that the current technology has the capacity to detect mosaicism in samples containing as low as 20% abnormal cells, for aberrations >10 Mb. Nevertheless, we observed that the log 2 (CN) values between samples with different proportions of aberrant cells were not always significantly different from each other. Therefore, exactly quantifying the proportion of aneuploid cells within a sample is not always accurate. Quantitative WGA bias is a principal source of this inaccuracy (Capalbo et al., 2017b) . In addition, the distinction between mosaic and meiotic aberrations from a single TE biopsy was not feasible in all instances. The poor predictive accuracy of a single TE biopsy to reflect the prevalence of mosaicism in the entire embryo makes defining a specific cut-off particularly difficult. As such, the transfer of mosaic embryos certainly warrants caution. Re-analysis of amplified DNA material with NGS determined that the rate of mosaicism within blastocysts leading to miscarriage was significantly higher than that within blastocysts leading to live births . Furthermore, we reveal reciprocal chromosomal aberrations in independent biopsies of the same embryo and uncover mitotic non- Total 24
Embryos were selected based on their original PGT-A profiles and evidence of mosaicism. These included abnormal, mosaic as well as more complex profiles, containing both uniform and mosaic aberrations. Embryo portions were compared to the original diagnosis, while concordance between the ICM and all three TE samples was further assessed. The chromosomal status of the ICM was further compared to the TE. The percentages are of the total number of pretested blastocysts.
disjunctions as a source of chromosomal heterogeneity. This may have implications regarding the strategy of selective transfer of embryos diagnosed with a mosaic monosomy (Preimplantation Genetic Diagnosis International Society, 2016; Sachdev et al., 2017) . A mitotic nondisjunction event may lead to the presence of a reciprocal trisomy within the same embryo, potentially leading to negative clinical outcomes (Capalbo et al., 2017b) .
The rate of mosaicism in human embryos remains controversial. Our estimate of~38% echoes previous reports. A large retrospective study of NGS data from multiple centres revealed a 33% mosaicism rate in donor oocyte-derived embryos (Sachdev et al., 2016) . Comparably, the embryos investigated in our untested group highlight the frequent incidence of mosaicism in good prognosis patients. In line with previous findings (Munné and Wells, 2017) we could not observe a significant effect of age on embryo mosaicism. Embryos with a euploid ICM often contained specific abnormalities confined to only one portion of the TE. Interestingly, the proportion of embryos with a euploid ICM and at least one aberrant TE profile was comparable amongst the untested and pretested embryos, at 20.6 and 25.0% respectively, and similar to previous reports (Garrisi et al., 2016b) . In such cases, mitotic errors may have occurred following ICM specification with abnormalities clonally accumulating within certain areas of the TE (Garrisi et al., 2016a) . Alternatively, aberrant cells may have been depleted from the ICM (Bolton et al., 2016) . Furthermore, 17.6% of embryos presented with mosaic or full aneuploidies within the ICM, while showing normal or mosaic TE profiles. In these cases, errors leading to mosaicism are likely to have occurred prior to ICM specification and appear more evenly distributed between blastocyst lineages. This may suggest that embryos with an abnormal ICM contain a greater number of aberrant cells, potentially impairing their developmental capacity compared to embryos with euploid ICMs (Bolton et al., 2016) . Data obtained from our pretested embryos suggest that blastocysts diagnosed with complex profiles (multiple aberrations) were more likely to contain chromosomally heterogenous cell populations. Furthermore, mosaicism occurred less frequently in meiotically abnormal embryos compared to euploid blastocysts (28.6 versus 48.1%, respectively). This supports the notion that genetically abnormal embryos may undergo negative selection during development (Bielanska et al., 2005) .
Compared to the original biopsy, we determined a high concordance for full aneuploidies, however mosaicism was confirmed less frequently. A recent study using NGS-comparing separate blastocyst segments obtained from mosaic embryos-could not confirm the original diagnosis in 50% of cases (McReynolds et al., 2016) . Our results are equally high (50%). Although, such findings imply false positive diagnoses, they also highlight the technological drawbacks of evaluating mitotic errors. According to a recent mathematical model, a biopsy of at least 27 cells allows for a minimal level of accurate statistical representation of the entire embryo (Gleicher et al., 2017) . Our ICM and TE samples contained~10-40 cells. Under this assumption, our data provide a more representative estimate of mosaicism in human blastocysts compared to routine PGT-A. Nevertheless, detecting mosaicism is inevitably determined by the number of cells analysed, thus, accurately estimating the rate of biological variability is exceptionally challenging. Detecting low levels of aneuploid cells within our samples is not possible if a considerable number of euploid cells are present. Conversely, as we are sampling numerous cells, mosaicism may be more readily diagnosed per embryo segment, compared to a standard PGT biopsy. Therefore, the number of cells analysed will inherently affect our reported analysis, but also ultimately the sensitivity and specificity of PGT-A. A uniform aberration diagnosed from a TE biopsy may in fact be obtained from an embryo with a euploid ICM, while a euploid TE biopsy may also be derived from a mosaic or abnormal blastocyst.
At present, chromosomal mosaicism is routinely diagnosed and included in PGT-A reports in many reproductive centres worldwide. However, both biological and methodological drawbacks must be evaluated to define more specific criteria for clinical management. Similarly, greater standardisation amongst IVF centres and more rigorous interpretation of data regarding the impact and prevalence of mosaicism in human blastocysts is essential. Continued monitoring of success rates and genetic evaluation of miscarriages may shed light on the diverse live birth outcomes following a diagnosis of mosaicism (Vera-Rodriguez and Rubio, 2017) . In the interim, the existence of false positives, false negatives, biological and technical variability, as observed in our study, must be acknowledged. Most importantly, communicating these limitations diligently to patients undergoing PGT-A and those considering the transfer of a mosaic embryo, is paramount.
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